3-Hour Virtual Seminar on Establishing a Robust Data Integrity Program

Data integrity is defined as the maintenance of, and the assurance of the accuracy and consistency of, data over its entire life-cycle. Data Integrity is a global issue with both FDA and the European Regulatory Agencies majorly focusing on the topic during compliance inspections. Multiple FDA warning letters and EU GMP non-compliance reports have highlighted major data integrity failures and falsification within companies around the globe. The regulatory concern has been responded to by both domestic and foreign governing agencies with the FDA, EMA, MHRA, WHO, and PIC/S all having recently published data integrity standards and guidelines.

This webinar will detail a data integrity governance program and principles for defining quality and data integrity into processes and systems. 

Areas Covered in the Session :

Session 1: 

^{Regulatory Guidance Review}

• FDA (CFR)
• EU (EurdraLex)
• PIC/S

^{Review all Elements Important to Maintaining Data Integrity}

• The ALCOA+ criteria for data integrity
• Data life cycle in the process workflow – managing controls
• Paper versus electronic systems
• Validation of computerized systems for data integrity controls

^{Key Data Integrity Topics}

• Recording results on paper. Good Documentation Practices
• Audit trail
• Data review
• File format
• Storage media
• Encryption
• User management (access control)
• Review of the data life cycle
• Handling of raw data
• Unauthorized access
• Appropriate access privileges for each user role
• Is my chromatographic system ready? Role of “test” injections
• Audit trails – options for older systems
• Manual chromatographic integration
• Standalone versus network systems
• Protecting electronic records of standalone systems

Session 2:

^{What are GMP-relevant Data?}

• GMP-relevant data – what are GMP-relevant data?
• Identifying data that has been changed or modified – how the system can help
• Review by exception – how technical controls can help
• Have you specified and validated these functions?

^{Why Is An Audit Trail Review Important?}

• Suspected data integrity violation – What do we need to do?

^{Can Spreadsheets meet Data Integrity requirements?}

• Problems with spreadsheets
• Good Practice for using spreadsheets in a regulated environment
• Building data integrity features into a spreadsheet

Session 3:

^{Common problems from FDA 483 observations and warning letters}

• How to avoid them

^{Case Study: Audit Trail to Review?}

1. Attendees will be presented with an overview of the audit trails within an application and the content of each one. Which audit trails should be reviewed and when?
2. Attendees will be provided with the output of an audit trail to review and see if any potential issues are identified for further investigation.
3. Attendees will be presented with a list of records to identify if they are GMP records. Examples from production, laboratory and QA examples of GMP-relevant data will be provided.

Who Should Attend:

• Quality Assurance Departments
• Quality Control Departments
• Research and Development Departments
• Regulatory Affairs Departments
• Manufacturing Departments
• Engineering Departments
• Operations Departments
• Production Departments
• Validation Departments

Course Director: KELLY THOMAS ‎

Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation. Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.